SECURE-IBD and J-COSMOS data showed that IBD patients receiving corticosteroids and a combination of anti-TNFα antibody and immunosuppressive drugs at the time of diagnosing COVID-19 pneumonia had a higher severity rate of COVID-19 compared to patients receiving anti-TNFα antibody monotherapy [5, 8]. Here, TNF is linked to inflammatory bowel disease.